Business Description
Sansure Biotech Inc
ISIN : CNE1000043J1
Share Class Description:
SHSE:688289: Class ATotal Employee Number:
2,128Compare
Compare
Traded in other countries / regions
688289.China Index Membership
SSE Composite IndexCSI 500 Index IPO Date
2020-08-28Description
Sansure Biotech Inc is engaged in the Research, development, production, and sales of diagnostic reagents and instruments.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.32 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 7.79 | |||||
Interest Coverage | 6.92 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.67 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -36.6 | |||||
3-Year EBITDA Growth Rate | -44.6 | |||||
3-Year EPS without NRI Growth Rate | -54.8 | |||||
3-Year Book Growth Rate | -1.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 23.07 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.06 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.55 | |||||
9-Day RSI | 61.21 | |||||
14-Day RSI | 56.76 | |||||
3-1 Month Momentum % | -20.12 | |||||
6-1 Month Momentum % | -27.48 | |||||
12-1 Month Momentum % | -32.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.26 | |||||
Quick Ratio | 3.9 | |||||
Cash Ratio | 3.24 | |||||
Days Inventory | 371.91 | |||||
Days Sales Outstanding | 160.68 | |||||
Days Payable | 330.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.4 | |||||
Dividend Payout Ratio | 2.65 | |||||
3-Year Dividend Growth Rate | -24.3 | |||||
Forward Dividend Yield % | 3.4 | |||||
5-Year Yield-on-Cost % | 2.6 | |||||
3-Year Average Share Buyback Ratio | 0.5 | |||||
Shareholder Yield % | -2.89 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.84 | |||||
Operating Margin % | 10.63 | |||||
Net Margin % | 9.79 | |||||
EBITDA Margin % | 9.46 | |||||
FCF Margin % | -10.24 | |||||
OCF Margin % | 13.52 | |||||
ROE % | 2.18 | |||||
ROA % | 1.64 | |||||
ROIC % | 3.21 | |||||
3-Year ROIIC % | -68.17 | |||||
ROC (Joel Greenblatt) % | 10.65 | |||||
ROCE % | 1.81 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 59.42 | |||||
Forward PE Ratio | 33.83 | |||||
PE Ratio without NRI | 75.81 | |||||
PS Ratio | 6.31 | |||||
PB Ratio | 1.24 | |||||
Price-to-Tangible-Book | 1.55 | |||||
Price-to-Operating-Cash-Flow | 46.22 | |||||
EV-to-EBIT | 42.36 | |||||
EV-to-EBITDA | 42.36 | |||||
EV-to-Revenue | 4.01 | |||||
EV-to-FCF | -39.13 | |||||
Price-to-GF-Value | 0.74 | |||||
Price-to-Projected-FCF | 0.69 | |||||
Price-to-Graham-Number | 2.29 | |||||
| Price-to-Net-Current-Asset-Value | 3.28 | |||||
| Price-to-Net-Cash | 6.04 | |||||
Earnings Yield (Greenblatt) % | 2.36 | |||||
FCF Yield % | -1.84 | |||||
Forward Rate of Return (Yacktman) % | -44.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sansure Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,603.391 | ||
| EPS (TTM) (Â¥) | 0.259 | ||
| Beta | 1.0685 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.3 | ||
| Volatility % | 21.05 | ||
| 14-Day RSI | 56.76 | ||
| 14-Day ATR (Â¥) | 0.614066 | ||
| 20-Day SMA (Â¥) | 14.901 | ||
| 12-1 Month Momentum % | -32.69 | ||
| 52-Week Range (Â¥) | 13.4 - 23.45 | ||
| Shares Outstanding (Mil) | 579.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sansure Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sansure Biotech Inc Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.261000 Cash Dividend | 2026-06-22 | 14.33 (+1.63%) | ||
| CNY 0.262000 Cash Dividend | 2025-09-23 | 20.30 (+0.35%) | ||
| CNY 0.275000 Cash Dividend | 2025-06-11 | 19.97 (-1.63%) | ||
| CNY 0.250000 Cash Dividend | 2024-09-26 | 17.12 (-0.52%) | ||
| 1.48:1 Stock Split | 2022-06-01 | 32.68 (+1.32%) |
Show
Entries
Sansure Biotech Inc Frequently Asked Questions
What is Sansure Biotech Inc(SHSE:688289)'s stock price today?
The current price of SHSE:688289 is ¥15.39. The 52 week high of SHSE:688289 is ¥23.45 and 52 week low is ¥13.40.
When is next earnings date of Sansure Biotech Inc(SHSE:688289)?
The next earnings date of Sansure Biotech Inc(SHSE:688289) is .
Does Sansure Biotech Inc(SHSE:688289) pay dividends? If so, how much?
The Dividend Yield %  of Sansure Biotech Inc(SHSE:688289) is 3.4% (As of Today), Highest Dividend Payout Ratio of Sansure Biotech Inc(SHSE:688289) was 5.83. The lowest was 0.11. And the median was 0.86. The  Forward Dividend Yield % of Sansure Biotech Inc(SHSE:688289) is 3.4%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sansure Biotech Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers